Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Nifedipine in Patients with Stable Angina Pectoris

Readman, A. S.

doi:10.2165/00003495-198900382-00015

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particu lar attention was paid to the patients' treat ment preference and to the symptoms and side effects experienced with each treatment. A preliminary account of this work has been published previously [8],…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Epanolol and Nifedipine in Stable Angina Patients: Results of a Multicentre Trial

Blake¹,

Berry²,

Readman³

et al. 1991

Cardiology

View full text Add to dashboard Cite

Epanolol (200 mg once daily) was compared with nifedipine (20 mg twice daily) in a multicentre, double-blind, randomised, crossover study in which 571 patients with stable angina pectoris were entered. Efficacy was assessed by anginal attack rate and short-acting nitrate consumption. Symptoms and treatment preference of the patients were assessed by questionnaires. Assessments were made at baseline and after each 4-week treatment period. Both treatments were equally efficacious as demonstrated by weekly anginal attack rates and nitrate usage. Of those patients who expressed a preference for treatment, 61 % expressed a preference for epanolol compared with 39% for nifedipine. Significantly fewer patients reported experiencing flushing, pedal oedema or feeling generally unwell (p < 0.01) during the epanolol treatment period. Patients withdrew from nifedipine treatment more often than from epanolol because of adverse effects. Hence, epanolol was found to be as efficacious as nifedipine in patients with stable angina pectoris, but exhibited a superior tolerability profile and was preferred by more patients.

show abstract

Section: Introductionmentioning

confidence: 99%

A Comparison of Epanolol and Nifedipine in Stable Angina Patients: Results of a Multicentre Trial

Blake¹,

Berry²,

Readman³

et al. 1991

Cardiology

View full text Add to dashboard Cite

show abstract

Epanolol as a Model for Assessing Patient Preference in Anti‐Anginal Drug Therapy

Blake¹,

Lewis²

1992

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Since drug therapy of angina is likely to produce a similar degree of efficacy for most drugs in common use, treatment choice should additionally focus on other factors, notably adverse events, quality of life, and convenience. Improvements in these factors can also lead to better compliance and can aid the doctor by cutting down the number of patient visits required to optimize therapy. The authors have evaluated the patient's overall assessment of symptomatic relief and adverse experiences in a comparative manner by means of the two-period crossover design using the patient's declared treatment preference as the primary measurement. This encapsulates several factors in a single assessment that can be understood by both physician and patient. The authors carried out two such studies of epanolol (Visacor), a novel anti-anginal agent with both beta-1 selective antagonist activity and also beta-1 selective partial agonist activity. In one study (n = 608) the comparator was metoprolol, and in the other (n = 571) it was nifedipine. This article describes and evaluates the methodology of these studies. To assess preference optimally, each patient had to receive both treatments in short but clinically relevant treatment periods, with no washout. Re-entry into the second period, after withdrawal from the first, was permitted. Both studies showed advantages for epanolol, more marked in the case of nifedipine, arising from equivalent efficacy but fewer adverse events.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Comparative Multicentre Study of the Tolerability and Efficacy of Epanolol versus Nifedipine in Patients with Stable Angina Pectoris

Cited by 2 publications

References 0 publications

A Comparison of Epanolol and Nifedipine in Stable Angina Patients: Results of a Multicentre Trial

A Comparison of Epanolol and Nifedipine in Stable Angina Patients: Results of a Multicentre Trial

Epanolol as a Model for Assessing Patient Preference in Anti‐Anginal Drug Therapy

Contact Info

Product

Resources

About